AbbVie receives EU approval for RINVOQ in giant cell arteritis
AbbVie $ABBV (+1,6 %) has great news from Europe: The European Commission (EC) has approved RINVOQ® (upadacitinib) for the treatment of adults with giant cell arteritis (GCA). This approval marks a significant step as it is the first oral therapy of its kind to be launched in the EU. The decision is based on the impressive results of the phase 3 SELECT-GCA study. Here, 46.4% of patients taking RINVOQ showed a sustained remission of the disease, compared to only 29% in the placebo group. Another plus point: the therapy enables less steroid exposure, which brings relief to many patients, as the side effects of steroid treatments are often burdensome. With this new indication, AbbVie is further expanding its position in the therapeutic area and demonstrating the importance of innovative approaches in medicine.
Levi's plans price increases due to US tariffs
In the USA, Levi Strauss $LEVI (+0,97 %) is confronted with a challenging situation: The potential price increases caused by President Donald Trump's tariffs could drive up the price of the brand's popular jeans. The company faces the challenge of coping with the increased costs without unduly burdening customers. It is considering how to adjust its pricing strategy in order to remain competitive. These considerations are particularly important in a highly competitive market in which every price increase harbors both opportunities and risks. Levi's must carefully consider how to respond to external economic factors in order to continue to successfully position its brand in the US market.
Sources: